University of Minnesota. Driven to Discover.
One patient is dead and one ill after contracting drug-resistant E coli after FMT.
A 3-track system would offer key advantages to the FDA's approach, the experts say.
Rates of prevention of recurrent C diff were similar, with fewer side effects.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.